secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2025-10-06T23:59:59+00:00
Accession:  0001104659-25-096935
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics treats first patient in Phase 1 OTS MAR-T cell study; well tolerated
--------------------------------------------------------------------------------

- First patient dosed at 100x10^6 cells in Phase 1 RAPID study evaluating MT-401 as Off-the-Shelf product.
- No treatment-related adverse events observed in first patient; safety consistent with prior MAR-T cell data.
- OTS product aims to accelerate time to treatment to as fast as 72 hours using healthy donor material.
- Non-dilutive funding from FDA, NIH SBIR, and CPRIT supports OTS program without affecting cash runway.
- APOLLO study in lymphoma reported 66% objective response rate and durable complete responses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465925096935/0001104659-25-096935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465925096935/tm2527906d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-096935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer